The selective responsiveness of NECs and AML cells to GSPT1 MGDs raises the intriguing possibility of extending this therapeutic approach to other malignancies with elevated CRBN expression or similar proteostasis dysregulation. Here, CRBN is linked to acute myeloid leukemia.